A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens

Mohamed El Kassas¹ (D), Mohamed Alboraie² (D), Mervat Naguib³ (D), Heba Omar⁴ (D), Adel El Tahan⁵ (D), Inas Moaz⁶ (D), Mohamed Abdellah² (D), Sameera Ezzat⁶ (D), Mohamed-Naguib Wifi³ (D), Ahmed F. Sherief⁷ (D), Mohamed Eltabbakh⁷ (D), Lobna Abdelsalam⁸ (D), Amal H. Eissa⁹ (D), Dalia Omran⁴ (D)

¹Endemic Medicine Department, Helwan University School of Medicine, Cairo, Egypt

²Department of Internal Medicine and and Hepatogastroenterology Unit, Al-Azhar University, Cairo, Egypt

³Internal Medicine Department, Cairo University School of Medicine, Cairo, Egypt

⁴Endemic Medicine and Hepato-Gastroenterology Department, Cairo University School of Medicine, Cairo, Egypt

⁵New Cairo Viral Hepatitis Treatment Unit, Cairo, Egypt

^eEpidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Shebin Elkom, Egypt

⁷Tropical Medicine Department, Ain Shams University School of Medicine, Cairo, Egypt

⁸Department of Clinical & Chemical Pathology, Cairo University School of Medicine, Cairo, Egypt.

⁹Clinical Pathology Department, Helwan University School of Medicine, Cairo, Egypt

Cite this article as: El Kassas M, Alboraie M, Naguib M, et al. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019; 30(8): 708-13.

ABSTRACT

Background/Aims: There is less data regarding the changes in body mass index (BMI) after treating hepatitis C virus (HCV) patients with new direct-acting antiviral agents (DAAs). This study aimed to assess the changes in BMI in chronic HCV patients treated with DAAs in Egypt and to explore other factors influencing this change.

Materials and Methods: The data of chronic HCV patients who received antiviral therapy with new DAAs in one of Egypt's specialized viral hepatitis treatment centers were retrospectively analyzed. In addition to the routine clinical and laboratory workup, changes in body weight during and after treatment were monitored and BMI was calculated. Viral load was measured at 12 weeks post-treatment to assess a sustained virological response. Patients with documented thyroid abnormalities, bariatric surgery, or ensuing special diets were excluded. BMI of >30 was taken as the cutoff for pa¬tients with obesity.

Results: The study included 162 patients with a mean age of 48.56±11.49 years, of whom 61.1% were males, 16% were treatment-experienced, 12% were diabetic, and 29% were obese. Treatment duration was 12 weeks in 84% of patients and 24 weeks in 16% of patients. There was a significant increase in BMI post-treatment as compared to pretreatment measures (28.68±5.35 vs 28.18±4.55) (p=0.03). BMI changes were constant regardless of cirrhosis or previous treatment experience.

Conclusion: Treatment of chronic HCV with DAAs was associated with increased body mass index. Further studies are needed to explore if this effect is secondary to treatment with DAAs or is an improvement in the liver function and lifestyle of treated patients. **Keywords:** BMI, DAAs, Egypt, HCV, obesity

INTRODUCTION

Chronic hepatitis C infection (CHC) is an important health problem and is a major cause of chronic liver disease, cirrhosis, hepatocellular carcinoma, and death (1). According to the recent models, approximately 71.1 (62.5-79.4) million persons are considered infected with chronic hepatitis C virus (HCV) globally (2). Several metabolic abnormalities have been reported with CHC, including metabolic syndrome, obesity, dyslipidemia, diabetes mellitus, and insulin resistance (3).

The role of obesity in antiviral treatment for CHC has been evaluated previously (4-6). Tarantino and his col-

leagues noted the negative impact of high body mass index (BMI) on the virological response to previously used pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy (7). BMI >30 kg/m² was considered as an independent predictor of non-response to PEG-IFN-based therapy (8). High BMI has been associated with greater degrees of steatosis and fibrosis (9, 10), insulin resistance (11-13), and increased systemic inflammatory responses such as high tumor necrosis factor (TNF) (14), all of which unfavorably affect the treatment outcome. On the other hand, weight loss has been reported during PEG-IFN/RBV therapy in 11%-29% of patients (18-21), which is associated with better treatment response (15-17).

Corresponding Author: Heba Omar; hebaomar1202@hotmail.com Received: August 18, 2018 Accepted: December 4, 2018

© Copyright 2019 by The Turkish Society of Gastroenterology · Available online at www.turkjgastroenterol.org DOI: 10.5152/tjg.2019.18514

Until recently, PEG-IFN/RBV had been considered the gold standard of care therapy for CHC patients with sustained virological response (SVR) rates ranging from 54%-56% (18-20). Introduction of well-tolerated, highly effective direct-acting antivirals (DAAs) improved the SVR rates and the patients' quality of life significantly (21,22). Data regarding changes in BMI after treatment with the new DAA are scarce. Previous reports show conflicting results of body weight changes after successful HCV eradication using INF-free regimens or interferon-containing DAA regimens (23,24). In this study, we aimed to assess the changes in BMI of Egyptian CHC patients treated with DAAs along with exploring the other factors influencing such changes.

MATERIALS AND METHODS Study design and patient recruitment

This was a retrospective cross-sectional study conducted between April 2015 and April 2017 at New Cairo Viral Hepatitis Treatment Center (NCVHTC) (25), a specialized facility affiliated with the Egyptian National Committee for Control of Viral Hepatitis (NCCVH). This center including others were the main pillars of the huge program aimed at controlling the HCV epidemic in Egypt (26,27). In this study, all patients with CHC who were referred to our center to receive DAAs were recruited. We included patients aged 18 years or older, with confirmed CHC that was proved by the positivity of HCV antibodies and HCV-RNA by PCR. The exclusion criteria according to Egyptian HCV treatment protocol were presence of significant liver disease (Child-Turcotte Pugh class C), hepatocellular carcinoma, extra-hepatic malignancies, pregnancy or unwilling to comply with 2 effective contraceptive methods, breastfeeding, or hypersensitivity to any of the study medications, in addition to factors that could impact the patients' weight, such as the presence of thyroid abnormalities, undergoing bariatric surgery, intentional diet control regimen, and the use of weight loss medications.

Procedure

All patients were subjected to full history-taking, including questions on concomitant medications and co-morbidities as well as a clinical examination, including the measurement of baseline weight and height, BMI calculation, and basic pretreatment laboratory investigations, including complete blood counts, liver and kidney functions tests, and hepatitis B surface antigen and alpha-fetoprotein tests. HCV load was measured using Cobas Ampli Prep/Cobas TaqMan HCV-RNA assay (Roche Diagnostics; Pleasanton, CA, USA) at baseline, at the end of treatment, and at 12 weeks post-treatment to assess SVR, which was defined as negative HCV PCR (<12 IU/mL according to the used test) at 12 weeks after the completion of the treatment course. Relapse is defined as having positive HCV PCR at 12 weeks after completion of the treatment course. The patients' weight in kilograms was measured using a standardized scale and height was measured using a standardized measuring tape (body meter measuring tape with wall mount) in meters. Changes in body weight were regularly monitored during (every 4 weeks) and after treatment (end of treatment and at 4 weeks and 12 weeks post-treatment) and BMI was calculated at every time point by dividing the person's weight in kg by the square of his or her height (in meter) expressed as kg/m^2 . BMI of >30 was taken as the cutoff for patients with obesity according to the Center for Disease Control and Prevention and the International Obesity Task Force criteria for obesity classification (28).

Treatment for chronic HCV

Patients were treated according to the issued protocol by NCCVH with different used regimens including Interferon/Sofosbuvir/Ribavirin (IFN/SOF/RBV), Paritaprevir/Ombitasvir/Ribavirin (PAR/OMP/RBV), Sofosbuvir/Daclatasvir (SOF/DCV), Sofosbuvir/Daclatasvir/Ribavirin (SOF/DCV/ RBV), Sofosbuvir/Ledipasvir/Ribavirin (SOF/LED/RBV), Sofosbuvir/Ribavirin (SOF/RBV), and Sofosbuvir/ Simeprevir (SOF/SIM). Choice of the used treatment regimen was based on the availability of medications and national HCV treatment recommendations at the time of enrollment.

Statistical analysis

The statistical analysis aimed at identifying the changes in BMI after treatment with DAAs (primary objective) and the effect of other parameters on this change (secondary objective). Categorical data were described using frequencies and percentages and continuous data were described using means, standard deviation (SD), medians, and ranges. Statistical analysis was conducted using SPSS version 20.0 (IBM Corp., Armonk, NY, USA). Categorical data were compared using the χ 2 test. BMI before and after treatment was compared using the Wilcoxon test. Percentage change in BMI was calculated by the following equation:

(BMI after treatment-Initial BMI) / Initial BMI*100

The percentage change BMI was then compared between categorical variables using the Mann-Whitney U test. Results were considered significant for a p-value < 0.05. All the tests were two-tailed.

	, , ,	
Saseline characteristic: All patients (n=		
Treatment received (n, %):		
IFN/SOF/RBV	2 (1.2)	
PAR/OMP/RBV	1 (0.6)	
SOF/DCV	91 (56.2)	
SOF/DCV/RBV	58 (35.8)	
SOF/LED/RBV	3 (1.9)	
SOF/RBV	6 (3.7)	
SOF/SIM	1 (0.6)	
HCV PCR log10 (IU/ml)	5.83±0.83	
ALT(IU/L)	49.31±31.23	
AST(IU/L)	50.35±31.88	
Albumin g/dL	4.02±0.45	
Total bilirubin mg/dL	0.84±00.42	
INR	1.11±0.13	
Hemoglobin	13.50±1.59	
WBC×103 mm ³	6.18±1.91	
platelets×103 mm³	202.51±78.44	
FBS mg/dL	105.67±27.10	
HbA1c	6.24±1.25	
AFP (IU/L) Median(IQR)	5 (3-10)	

Table 1. Baseline characteristics of the study group.

Study oversight and ethical considerations

The current study was conducted in accordance with Good Clinical Practice guidelines laid down in the Helsinki Declaration of 1975 and was approved by the ethical committee of the National Hepatology and Tropical Medicine Research Institute in Cairo. Informed consent was obtained from all participants during the enrollment phase before the start of any treatment or data collection.

RESULTS

Our study included 162 patients with a mean age of 48.56 (\pm 11.498) years. The percentage of male patients was higher than female patients (61.1% Vs 38.9%). About 29% of our patients suffered from obesity (BMI >30 kg/m²), 12% were diabetic, 11% were hypertensive, and 16% were treatment-experienced. Ultrasound examination of



Figure 1. Changes in BMI before and after treatment with DAAs.

the liver confirmed the presence of liver cirrhosis in 13% of the patients while the remaining 87% were non-cirrhotics. The most commonly received DAAs regimen was SOF/DCV±RBV (92% of patients) and the least used regimens were PAR/OMP/RBV and SOF/SIM (0.6% each). The details of the used treatment regimens and baseline laboratory parameters are presented in Table 1.

Treatment duration was 12 weeks in 84% of the patients and 24 weeks in 16% of the patients. There was a statistically significant increase in BMI (28.68±5.35 versus 28.18±4.55) in patients successfully treated with DAAs 12 weeks after completing the course of treatment (p=0.03) (Figure 1). Maximum percentage change of BMI was 36% and the minimum percentage change of BMI was 22.5%, while the mean percentage change (±SD) was 1.63±10.62%. There was no significant difference in BMI percentage change between patients without liver cirrhosis (n=143 patients) and those with liver cirrhosis (n=21 patients). Mean ± SD of BMI percentage change was 2.07±11.43% in patients without liver cirrhosis and 0.18±10.41% in patients with liver cirrhosis (p=0.59). Also, there was no significant difference in BMI percentage change between both treatment-naive and treatment-experienced patients (1.39±11.99% and $4.17\pm6.11\%$) respectively with p=0.12 (Table 2).

Table 2. Changes	s in	BMI	in	both	groups
------------------	------	-----	----	------	--------

	SVR grou			
	Pretreatment Mean±SD	Post-treatment Mean±SD	р	
BMI (kg/m²)	28.18±4.55	28.68±5.35	*0.03	
Subgroups of patients with SVR				
BMI percent change (%)	Non-cirrhotic (n=143) Mean±SD	Cirrhotic (n=21) Mean±SD		
	2.07±11.43	0.18±10.41	**0.59	
BMI percent change (%)	Naive (n=138) Mean±SD	Experienced (n=26) Mean±SD		
	1.39±11.99	4.17±6.11	**0.12	
*Wilcoxon test. **Mann-Whitney U test.				

DISCUSSION

IFN-free DAA regimens for the treatment of CHC have demonstrated more favorable clinical outcomes, a considerable improvement in liver function, an improvement in the quality of life, and an excellent safety profile (29-33). However, the effects of an IFN-free era of HCV treatment on the weight of treated patients have not been investigated in detail. The purpose of this study was to determine the degree of weight change that occurs during the course of DAA treatment in CHC patients and to determine the factors that could affect the patterns of weight change. Most patients in the current study were found not to have obesity at the time of enrollment, but significant weight gain ensued over the course of and after the treatment. Although malnutrition is a well-recognized condition in patients with liver cirrhosis (34), the change in BMI did not differ in treated patients whether they had cirrhosis or not.

Previous studies have shown a reduction in the body weight of patients treated with interferon-based therapy (15,35,36). There are only a few studies that have investigated the effect of DAAs on BMI. The same finding was constant with first-generation proteases that were given in combination with interferon. A study that evaluated the use of PEG-IFN/RBV/telaprevir triple therapy showed that this regimen was associated with more reduction in body weight than PEG-IFN/RBV treatment (24). However, the newer generation DAAs have demonstrated an increase in body weight following treatment of CHC (27).

Our patients who had SVR to DAA treatment showed a 1.93% (±11.30%) increase in their BMI. These results are consistent with a recent study showing that SVR sec-

ondary to DAA treatment was associated with weight gain in a cohort of veterans treated for HCV (37). Another study by Schlevogt and his colleagues demonstrated that 44% of treated subjects had weight gain at long-term follow-up after HCV clearance (29). The authors even demanded identification of the precise subgroup and explanatory mechanisms for this kind of weight gain as they were concerned that such an outcome might erase the beneficial effects of HCV clearance by worsening the hepatic steatosis and aggravating the onset of metabolic syndrome. The reason for such mechanisms leading to an increase in BMI with DAA treatment is unclear. It may be related to the improvement of psychological state, i.e., an increase in appetite or taste sensation with a clearance of HCV (38). Another explanation is that successful treatment is associated with a reduction in inflammatory cytokines and TNF-alpha, both of which act as cofactors in weight loss (39,40).

The limitations of this study are that firstly, it was a cross-sectional retrospective study with small sample size. Due to the unavailability of weight and height for many patients in the database, we did not have enough matching numbers of treatment failure patients with recorded BMI before and after treatment. That is also why we could not include a control group for comparison. Such limitations could be rectified by further prospective studies including all the influential parameters that could be debatable in such a task. Secondly, the patients' diet and psychological condition had not been assessed in detail. Lastly, most of the patients were receiving SOF/DCV (±RBV) regimens, which are the main line of therapy in our national program (41). The small number of patients in other treatment regimens made it difficult to compare

the effect of the used regimen, and hence, further studies to compare different regimens are needed. Long-term prospective studies are also needed to assess the permanence of these changes in BMI and their effect on hepatic steatosis and fibrosis and to evaluate the effect of this increase in BMI on the outcomes of HCV treatment.

In conclusion, the current study showed a significant increase in BMI in patients with SVR treated with DAAs for chronic HCV. However, the precise mechanism for this change and its long-term effect needs further evaluation.

Ethics Committee Approval: Ethics committee approval was received from the Ethics Committee of the National Hepatology and Tropical Medicine Research Institute.

Informed Consent: Written informed consent was obtained from the patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Design -M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Supervision - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Resources -M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Materials - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Data Collection and/or Processing - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Analysis and/or Interpretation - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Literature Search - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Writing Manuscript - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.; Critical Reviews - M.E.K., M.A., M.N., H.O., A.E.T., I.M., M.A., S.E., M.N.W., A.S., M.E., L.A., A.H.E., D.O.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. WHO (2017). Global hepatitis report. Available from: http://www. who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed on January 2nd, 2018.

2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 161-76. [CrossRef] 3. Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016; 22:1461-76. [CrossRef]

4. Lo lacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181-91. [CrossRef] 5. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44. [CrossRef] 6. Walsh MJ, Jonsson JR, Richardson MM, et al. Nonresponse to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype. Gut 2006; 55: 529-35. [CrossRef]

7. Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006; 21: 1266-8. [CrossRef]

8. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44. [CrossRef]

9. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-9. [CrossRef]

10. Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40: 147-54. [CrossRef]

11. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-14. [CrossRef]

12. Hsieh MH, Lee LP, Hsieh MY, et al. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis 2007; 60: 377-81.

13. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90. [CrossRef] 14. Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5: 528-40. [CrossRef]

15. Chung RT, Poordad FF, Hassanein T, et al. Association of host pharmacodynamic effects with virologic response to pegylated interferon alpha-2a/Ribavirin in chronic hepatitis C. Hepatology 2010; 52: 1906-14. [CrossRef]

16. Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leucopenia and thrombocytopenia associated with sustained virological response to hepatitis C treatment. Int J Med Sci 2010; 7: 36-42. [CrossRef]

17. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/Ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepatitis 2010; 17: 139-47. [CrossRef]

18. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: 237-44. [CrossRef]

19. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65. [CrossRef]

20. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82. [CrossRef]

21. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62: 87-99. [CrossRef]

22. Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol 2014; 6: 4-15. [CrossRef]

23. Schlevogt B, Deterding , Port K, et al. Journal of Hepatology 2016; 64: S750. [CrossRef]

24. Nomura H, Miyagi Y, Tanimoto H, Kawano A, Yamashita N. Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss. Intern Med 2014; 53: 2567-73. [CrossRef]

25. El Kassas M, Alboraie M, Omran D, et al. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol 2018; 12: 1265-72. [CrossRef]

26. El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat 2017; 24: 262-7. [CrossRef]

27. Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017; 15; 17-25. [CrossRef]

28. Moselakgomo VK, Van Staden M. Diagnostic Comparison of Centers for Disease Control and Prevention and International Obesity Task Force criteria for obesity classification in South African children. Afr J Prim Health Care Fam Med 2017; 9: 1-7. [CrossRef]

29. Schlevogt B, Deterding K, Port K, et al. Weight gain after IFN-free cure of chronic hepatitis C: A potential concern? J Hepatol 2016; 64: S750. [CrossRef]

30. Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int 2017; 37: 534-41. [CrossRef]

31. Youssef NF, El Kassas M, Farag A, Shepherd A. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. BMC Gastroenterol 2017; 17: 18. [CrossRef] 32. Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res 2015; 6: 301-10. [CrossRef]

33. El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf 2016; 15: 1643-52. [CrossRef]

34. Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. Nutr Clin Pract 2013; 28: 15-29. [CrossRef]

35. Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. J Viral Hepatitis 2005; 12: 531-5. [CrossRef]

36. Bani-Sadr F, Lapidus N, Melchior JC, et al. Severe weight loss in HIV/HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepatitis 2008; 15: 255-60. [CrossRef]

37. Albert Do, Esserman D, Tate JP, et al. Weight change after receipt of direct-acting antiviral agents for hepatitis C. Gastroenterology 2017; 152: S1163. [CrossRef]

38. Musialik J, Suchecka W, Klimacka-Nawrot E, Petelenz M, Hartman M, Błońska-Fajfrowska B. Taste and appetite disorders of chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2012; 24: 1400-5. [CrossRef]

39. Villani R, Facciorusso A, Bellanti F, et al. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS ONE 2016; 11: e0167934. [CrossRef] 40. Kayacan O, Karnak D, Beder S, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 2006; 29: 328-35. [CrossRef]

41. Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther 2017; 47: 421-31. [CrossRef]